These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30393044)

  • 1. Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.
    De Santis F; Del Vecchio M; Castagnoli L; De Braud F; Di Cosimo S; Franceschini D; Fucà G; Hiscott J; Malmberg KJ; McGranahan N; Pietrantonio F; Rivoltini L; Sangaletti S; Tagliabue E; Tripodo C; Vernieri C; Zitvogel L; Pupa SM; Di Nicola M
    Cytokine Growth Factor Rev; 2018 Dec; 44():1-10. PubMed ID: 30393044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative Therapy, Monoclonal Antibodies and Beyond.
    Di Nicola M; Apetoh L; Bellone M; Colombo MP; Dotti G; Ferrone S; Muscolini M; Hiscott J; Anichini A; Pupa SM; Braud F; Del Vecchio M
    Cytokine Growth Factor Rev; 2017 Dec; 38():1-9. PubMed ID: 29029813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer innovative therapy: Highlights from the ninth annual meeting.
    Volpari T; De Santis F; Bracken AP; Pupa SM; Buschbeck M; Wegner A; Di Cosimo S; Lisanti MP; Dotti G; Massaia M; Pruneri G; Anichini A; Fortunato O; De Braud F; Del Vecchio M; Di Nicola M
    Cytokine Growth Factor Rev; 2020 Feb; 51():1-9. PubMed ID: 31862236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy.
    Yi M; Jiao D; Qin S; Chu Q; Li A; Wu K
    Integr Cancer Ther; 2019; 18():1534735419876351. PubMed ID: 31517538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.
    Shi T; Ma Y; Yu L; Jiang J; Shen S; Hou Y; Wang T
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29735917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of intestinal microbiota in response to cancer immunotherapy.
    Cong J; Zhang X
    Eur J Clin Microbiol Infect Dis; 2018 Dec; 37(12):2235-2240. PubMed ID: 30209679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
    Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
    Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Voluntary mediation in healthcare disputes: the experience of the "Fondazione IRCCS Istituto Nazionale dei Tumori" in Milan (Italy)].
    Tereanu C; Bettega S; Regalia E; Mazza R; Greco M; Lozza L; Saita L; Borreani C; Quattrocolo A
    Ig Sanita Pubbl; 2014; 70(1):29-40. PubMed ID: 24770363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The organization of clinical trials for oncology at IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale" Napoli and the impact of the OECI accreditation process.
    De Feo G; D'Ambrosio F; Palmieri G; Perrone F; Ciliberto G
    Tumori; 2015; 101 Suppl 1():S33-7. PubMed ID: 27096270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Antibodies in Cancer Therapy.
    Gasser M; Waaga-Gasser AM
    Adv Exp Med Biol; 2016; 917():95-120. PubMed ID: 27236554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy 2005: Mainz, Germany, 12-13 May 2005.
    Britten CM; Gouttefangeas C; Kreiter S
    Cancer Immunol Immunother; 2006 Apr; 55(4):475-80. PubMed ID: 16193336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy and lung cancer: current developments and novel targeted therapies.
    Domingues D; Turner A; Silva MD; Marques DS; Mellidez JC; Wannesson L; Mountzios G; de Mello RA
    Immunotherapy; 2014; 6(11):1221-35. PubMed ID: 25496336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications.
    Guven DC; Aktas BY; Simsek C; Aksoy S
    Future Oncol; 2020 Mar; 16(9):497-506. PubMed ID: 32100550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental?
    Hekmatshoar Y; Rahbar Saadat Y; Hosseiniyan Khatibi SM; Ozkan T; Zununi Vahed F; Nariman-Saleh-Fam Z; Pourghassem Gargari B; Sunguroglu A; Zununi Vahed S
    Life Sci; 2019 Sep; 233():116680. PubMed ID: 31344431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of immunotherapy in older adults: New treatments, new toxicities?
    Helissey C; Vicier C; Champiat S
    J Geriatr Oncol; 2016 Sep; 7(5):325-33. PubMed ID: 27318796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bugs in the system: bringing the human microbiome to bear in cancer immunotherapy.
    Strouse C; Mangalam A; Zhang J
    Gut Microbes; 2019; 10(2):109-112. PubMed ID: 30183502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK cell-based immunotherapy for cancer.
    Fang F; Xiao W; Tian Z
    Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.